Byondis
Ellen Mattaar is a highly experienced senior scientist currently working at Byondis since April 2020. Prior to this role, Ellen served as a specialist in protein interactions at Synthon from May 2012 to April 2020, where responsibilities included supporting users of advanced protein interaction instruments. Earlier experience includes a temporary position as an analytical technician/senior scientist at Merck and a long tenure at Merck as a senior scientist from November 1988 to June 2012. Ellen began her career as an assistant scientist at the Gaubius Institute and Dr. Daniel den Hoed Clinic, focusing on cholesterol metabolism and primary breast tumor cell culture. Ellen holds a Bachelor’s degree in Biochemistry from the van 't Hoff Instituut (Hogeschool Rotterdam).
This person is not in any teams
This person is not in any offices
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.